Navigation Links
Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
Date:6/21/2010

article formulation for intensive physical characterization, in-vitro studies, and in-vivo pharmacology and toxicology protocols to support an eventual investigational new drug (IND) filing with the U.S. Food and Drug Administration.

About Cephalon, Inc.

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries. More information on Cephalon and its products is available at http://www.cephalon.com/.  

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of impro
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
2. Isis Pharmaceuticals to Present at The Wells Fargo 2010 Healthcare Conference
3. Obamas Healthcare Reform Bill and its Impact on the U.S. Healthcare Markets (Pharmaceuticals, Medical Devices and Health Insurance)
4. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
5. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
6. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
7. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
8. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
9. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
10. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
11. Jazz Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014 /CNW/ - Health Minister Rona ... will make available for donation over $2.5 million in personal ... aid in the global response to the Ebola outbreak in ... WHO reported a shortage of equipment in the affected countries ... by front-line workers in the affected countries. ...
(Date:9/15/2014)... 15, 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... company with a focus on Omega-3 therapies for ... the Board of Directors approved the granting of ... the close of business on Friday, September 12, ... common shares of the Company were granted in ...
(Date:9/15/2014)... /PRNewswire-iReach/ -- Asthma is a chronic inflammatory lung ... most commonly starts in childhood. It is a ... airways, leading to airflow limitation and airway hyper-responsiveness ... endogenous and exogenous irritants. Exposure to irritants instigates ... the airways, tightening of the respiratory muscles, and ...
Breaking Medicine Technology:Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 2Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 3Pivotal Therapeutics Grants Incentive Stock Options 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5
... DIEGO, Feb. 29, 2012  Polaris Group (Polaris) today announced ... Phase 1 clinical trial evaluating its lead cancer therapeutic, ... emphasis on leukemia, lymphoma and sarcoma cancers. These three ... in the pediatric population. Patients with advanced ...
... Md., Feb. 29, 2012  Northwest Biotherapeutics (OTC.BB: NWBO) (NW ... Ph.D., MA, MBA, will be presenting at the Cancer ... pm ET on Wednesday, February 29, 2012, in Boston, Massachusetts ... (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ...
Cached Medicine Technology:Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma 2Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma 3NW Bio to Present at the Cancer Immunotherapy Summit 2NW Bio to Present at the Cancer Immunotherapy Summit 3NW Bio to Present at the Cancer Immunotherapy Summit 4
(Date:9/16/2014)... 16, 2014 Wholelifeinsurancecompanies.org has released a ... life insurance with a bad heart condition. , Clients ... affordable life insurance if they compare quotes. Most agencies ... decision depend on the actual and past medical condition. ... caused several heart attacks in the past, his or ...
(Date:9/16/2014)... comparison of five-year sexual function outcomes, as ... radiotherapy (EBRT) versus combination EBRT plus brachytherapy, ... therapy makes cure possible without compromising long-term ... at the American Society for Radiation Oncology,s ... study examined the patient-reported outcomes of 91 ...
(Date:9/16/2014)... than any other workplace incident, a statistic that transport ... conference being hosted by QUT,s Centre for Accident Research ... Safety in Transport Conference (OSIT) to be held on ... together experts from all facets of transport safety including ... and safety. , CARRS-Q research fellow Darren Wishart said ...
(Date:9/16/2014)... have developed a new cocktail that is highly ... pluripotent stem cells. , Regenerative medicine is a ... lost or damaged cells, tissues or organs through ... embryos can trigger ethical concerns, a good solution ... state using a combination of reprogramming factors. ...
(Date:9/16/2014)... 2014 An experimental positron emission tomography ... while a person is still alive, according to a ... at Mount Sinai, and at Molecular Neuroimaging (MNI) LLC ... journal Translational Psychiatry. , Specifically, the study results suggest ... is designed to latch onto a protein called tau ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function 2Health News:Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function 3Health News:CARRS-Q Host International Transport Safety Conference 2Health News:Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4
... His Royal Highness, The Duke of York,was the ... to mark the United States,launch of UK-based specialty ... US product, Sancuso, is currently under,consideration for licensing ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080214/NYTH111 ), Prince Andrew ...
... validity of self-reported tobacco use in research, care , , ... more likely than younger ones to deny they smoke ... That,s the conclusion of a study that analyzed data ... took part in the third National Health and Nutrition ...
... Dividend, ACTON, Mass., Feb. 14 Psychemedics,Corporation (Amex: ... results for the period ended December 31, 2007, which ... The Company,also announced a quarterly dividend of $0.15 per ... 2008 to be paid on March 21, 2008.,This will ...
... Weight Watchers,International, Inc. (NYSE: WTW ) today announced results ... 2007., Fourth Quarter 2007 Results, For the fourth ... $344.0 million. Fully diluted earnings per share in the fourth,quarter ... period. The prior,year included a benefit of $0.06 per share ...
... N.J., Feb. 14 TeamStaff, Inc.,(Nasdaq: TSTF ), ... announced its financial results for the first,quarter ended December ... months ended December 31, 2007 was,$0.1 million as compared ... last year. Income from continuing operations was $0.04 million ...
... 14 /PRNewswire-USNewswire/ - The Foundation,for Taxpayer and Consumer ... HMO,regulator calling for swift action to end Blue ... medical records for any,excuse to dump patients who ... the Los Angeles Times on Wednesday,that the practice ...
Cached Medicine News:Health News:His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States 2Health News:His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States 3Health News:Older Smokers More Likely to Deny Habit 2Health News:Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue 2Health News:Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue 3Health News:Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue 4Health News:Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue 5Health News:Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue 6Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 2Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 3Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 4Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 5Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 6Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 7Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 2Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 3Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 4Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 5Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 6Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 7Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 8Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 9Health News:FTCR: Gov. Schwarzenegger Must Follow Through on Call to Ban Blue Cross From Using Doctors as Double-Agents to Dump Sick Patients 2
... three-dimensional VCS technology, providing ... efficiency in white cell ... With its reputation for ... is an affordable solution ...
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL....
For the quantitative determination of Creatine Kinase in serum....
For the qualitative determination of magnesium in serum....
Medicine Products: